Amneal to close it Hayward, California-based facilities and operations25 May 2018
Company to streamline operations and capture cost synergies.
Amneal Pharmaceuticals is to streamline operations following a comprehensive analysis of its current and future product portfolios, plant capacities, overlapping capabilities and cost structure as a result of the recent business combination with Impax Laboratories. As a result, the company will close its Hayward, California-based facilities and operations.
The company will immediately implement plans to phase out the Hayward facilities with an expected completion timeline of approximately 15 months, nearly one-year ahead of schedule. Amneal expects to transfer products manufactured at the Hayward facility to the company's lower-cost facilities in the US and India.
"We are taking these steps to streamline our operations, accelerate savings and generate resources to drive organic growth as well as pursue external growth opportunities," said Rob Stewart, President and CEO of Amneal. "The acceleration of these initiatives primarily in manufacturing and R&D operations, combined with our large and diverse generic pipeline of potential high-value product opportunities, will help us achieve our commitment to generate approximately $1.1 billion of adjusted EBITDA by the end of 2020. Our announcement is not expected to materially impact our full year 2018 adjusted EBITDA guidance of $600 million to $650 million and full year adjusted EPS of $0.95 to $1.10 per diluted share. We do expect a significant favorable impact beginning in 2019."
Mr Stewart continued: "I recognize that these types of announcements are difficult for our colleagues. We have announced and are committed to implementing a comprehensive transition plan. We will also work toward an orderly wind-down of the Hayward facilities to ensure these actions cause minimal disruptions to customers and patients. I have asked teams across our company for their full support of our colleagues in Hayward as we work together through this difficult transition."
Amneal expects the facility closures to reduce its workforce by approximately 550 positions. Additional details regarding the financial impact and pre-tax restructuring charges will be provided in a future company filing.
Compact serialization-ready manual workstation
11 Aug 2018
A cost-effective and space-saving solution for serializing cartons and performing multi-level aggregation on cases and pallets.Read more
Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines
8 Aug 2018
Company moves away from manual processing in favour of automated, scalable platforms.Read more
BASF receives award for its portfolio of natural cosmetic ingredients
7 Aug 2018
Company recognised for its innovation and continual delivery of new natural ingredients.Read more
Extended distribution agreement enables customers to continuously improve their bioprocesses
6 Aug 2018
Agreement includes Pall's next-generation Kaneka KanCapA 3G sorbent for the primary capture of mAbs from clarified cell culture.Read more
A new era for migraine patients
6 Aug 2018
EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.Read more
Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island
3 Aug 2018
The plant will be first-of-its-kind in the US.Read more
Croda invests in SiSaf’s novel bio-courier technology
3 Aug 2018
ProSilic will give Croda’s customers access to the next generation of targeted and controlled drug delivery.Read more
Breast cancer device receives FDA approval
3 Aug 2018
The first non-radioactive, dual-tracer for sentinel lymph node biopsy approved in the US.Read more
Building contingency plans for an ambiguous post-Brexit market
31 Jul 2018
One company's positive approach to Brexit preparations, despite the lack of definition.Read more
Cherwell publishes guide on environmental monitoring processes and validation
31 Jul 2018
Supporting EM programs in preparation for proposed EU GMP Annex 1 changes.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation